Cortexyme Inc (CRTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
N/A
Employees:
269 EAST GRAND AVE, SOUTH SAN FRANCISCO, CA 94080
415-910-5717

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 82.599 Million Shares Outstanding30.146 Million Avg 30-day Volume 411.687 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.73
Price to Revenue0.0 Debt to Equity0.0 EBITDA-177.421 Million
Price to Book Value1.7544 Operating Margin0.0 Enterprise Value75.935 Million
Current Ratio9.923 EPS Growth-0.061 Quick Ratio9.426
1 Yr BETA 1.5129 52-week High/Low 121.98 / 2.64 Profit Margin0.0
Operating Cash Flow Growth-21.9277 Altman Z-Score4.1889 Free Cash Flow to Firm -72.16 Million
Earnings Report2022-08-04
View SEC Filings from CRTX instead.

View recent insider trading info

Funds Holding CRTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LOW PHILIP S

  • Director
0 2022-05-19 2

THYE DIRK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2022-05-19 2

SMITH KAREN L. CHIEF MEDICAL OFFICER

  • Officer
0 2022-05-19 2

LAMOND DAVID

  • Director
3,883,660 2022-05-19 2

HANNAH BRENDAN CHIEF BUSINESS OFFICER

  • Officer
0 2022-05-19 2

SABBAGH MARWAN

  • Director
0 2022-03-14 2

LOWE CHRISTOPHER P. INTERIM CEO, COO & CFO

  • Officer
265,000 2022-03-03 6

MONOHON TED CHIEF ACCOUNTING OFFICER & VP

  • Officer
34,000 2022-03-03 2

MCDOWELL CARYN GORDON CHIEF LEGAL & ADM. OFFICER

  • Officer
140,000 2022-03-03 2

DETKE MICHAEL J. CHIEF MEDICAL OFFICER

  • Officer
140,000 2022-03-03 4

HOLSINGER LESLIE EVP, PRECLINICAL DEVELOPMENT

  • Officer
159,000 2022-03-03 2

LYNCH CASEY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
440,000 2022-01-03 2

DOMINY STEPHEN S. CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
125,000 2022-01-03 2

MCLOUGHLIN MARGARET

  • Director
84,911 2021-10-08 4

RYAN UNA S

  • Director
11,029 2021-06-16 1

SENNER CHRISTOPHER J.

  • Director
11,029 2021-06-16 1

EPIQ CAPITAL GROUP, LLC

BOEDING CHAD

  • FORMER 10% OWNERCEO OF FORMER 10% OWNER
No longer subject to file 2020-12-31 0

YOUNG KEVIN

  • Director
0 2020-06-08 0

PFIZER INC

PFIZER STRATEGIC INVESTMENT HOLDINGS LLC

PFIZER VENTURES (US) LLC

  • 10% Owner
No longer subject to file 2020-06-03 0

GAFRIC KRISTEN SVP, LEGAL & ADMINISTRATION

  • Officer
0 2020-02-06 0

CHIESI FARMACEUTICI SPA

  • 10% Owner
No longer subject to file 2014-02-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SMITH KAREN L. - Officer CHIEF MEDICAL OFFICER

2022-05-23 20:24:15 -0400 2022-05-23 A 1,365,449 a 1,365,449 direct

THYE DIRK - Director - Officer CHIEF EXECUTIVE OFFICER

2022-05-23 20:29:04 -0400 2022-05-23 A 1,979,650 a 1,979,650 direct

HANNAH BRENDAN - Officer CHIEF BUSINESS OFFICER

2022-05-23 20:07:34 -0400 2022-05-23 A 353,656 a 353,656 direct

THYE DIRK - Director - Officer CHIEF EXECUTIVE OFFICER

2022-05-23 20:29:04 -0400 2022-05-19 A 64,589 a 64,589 direct -3.5211 0.0 1 -3.5211 2

HANNAH BRENDAN - Officer CHIEF BUSINESS OFFICER

2022-05-23 20:07:34 -0400 2022-05-19 A 16,224 a 16,224 direct -3.5211 0.0 1 -3.5211 2

LAMOND DAVID - Director by david a. lamond trust dated 2006

2022-05-23 20:09:08 -0400 2022-05-19 A 200,002 a 1,734,722 indirect -3.5211 0.0 1 -3.5211 2

LOW PHILIP S - Director

2022-05-23 20:17:43 -0400 2022-05-19 A 455,309 a 455,309 direct -3.5211 0.0 1 -3.5211 2

LOW PHILIP S - Director by philip s. low revocable trust

2022-05-23 20:17:43 -0400 2022-05-19 A 63,974 a 63,974 indirect -3.5211 0.0 1 -3.5211 2

SMITH KAREN L. - Officer CHIEF MEDICAL OFFICER

2022-05-23 20:24:15 -0400 2022-05-19 A 151,799 a 151,799 direct

THYE DIRK - Director - Officer CHIEF EXECUTIVE OFFICER

2022-05-23 20:29:04 -0400 2022-05-19 A 206,391 a 206,391 direct

HANNAH BRENDAN - Officer CHIEF BUSINESS OFFICER

2022-05-23 20:07:34 -0400 2022-05-19 A 103,500 a 103,500 direct

LOW PHILIP S - Director

2022-05-23 20:17:43 -0400 2022-05-19 A 22,058 a 22,058 direct

SMITH KAREN L. - Officer CHIEF MEDICAL OFFICER

2022-05-23 20:24:15 -0400 2022-05-19 A 24,336 a 24,336 direct -3.5211 0.0 1 -3.5211 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CORTEXYME INC CRTX 2022-05-26 22:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 21:45:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 21:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 20:45:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 20:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 19:45:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 19:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 18:45:04 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 18:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 17:45:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 17:15:03 UTC -3.7941 4.6141 450000
CORTEXYME INC CRTX 2022-05-26 16:45:04 UTC -3.7919 4.6119 450000
CORTEXYME INC CRTX 2022-05-26 16:15:03 UTC -3.7919 4.6119 450000
CORTEXYME INC CRTX 2022-05-26 15:45:03 UTC -3.7919 4.6119 450000
CORTEXYME INC CRTX 2022-05-26 15:15:03 UTC -3.7919 4.6119 300000
CORTEXYME INC CRTX 2022-05-26 14:45:03 UTC -3.6923 4.5123 300000
CORTEXYME INC CRTX 2022-05-26 14:15:03 UTC -3.6923 4.5123 300000
CORTEXYME INC CRTX 2022-05-26 13:45:05 UTC -3.6923 4.5123 300000
CORTEXYME INC CRTX 2022-05-26 13:15:03 UTC -3.6923 4.5123 300000
CORTEXYME INC CRTX 2022-05-26 12:45:03 UTC -3.6923 4.5123 300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments